

# Resource Summary Report

Generated by SPARC SAWG on Aug 17, 2026

## CD8a Antibody, anti-mouse, PE-Vio® 770, REAfinity™

RRID:AB\_2733250

Type: Antibody

### Proper Citation

Miltenyi Biotec Cat# 130-119-123, RRID:AB\_2733250

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2733250](http://antibodyregistry.org/AB_2733250)

**Proper Citation:** Miltenyi Biotec Cat# 130-119-123, RRID:AB\_2733250

**Target Antigen:** CD8a

**Host Organism:** human

**Clonality:** monoclonal

**Comments:** Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-109-327. (RRID:AB\_2659499).  
Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-109-249. (RRID:AB\_2659500).

**Antibody Name:** CD8a Antibody, anti-mouse, PE-Vio® 770, REAfinity™

**Description:** This monoclonal targets CD8a

**Target Organism:** mouse

**Clone ID:** clone REA601

**Antibody ID:** AB\_2733250

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-119-123

**Record Creation Time:** 20250819T231639+0000

**Record Last Update:** 20250820T045036+0000

---

## Ratings and Alerts

No rating or validation information has been found for CD8a Antibody, anti-mouse, PE-Vio® 770, REAfinity™.

No alerts have been found for CD8a Antibody, anti-mouse, PE-Vio® 770, REAfinity™.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [SPARC SAWG](#) .

Krug A, et al. (2024) Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment. Journal of experimental & clinical cancer research : CR, 43(1), 43.

Colucci M, et al. (2024) Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. Cancer cell.

Martinez-Turtos A, et al. (2022) IRE1 $\gamma$  overexpression in malignant cells limits tumor progression by inducing an anti-cancer immune response. Oncoimmunology, 11(1), 2116844.